Voglibose

CAS 83480-29-9

Also known as: Glustat

Voglibose is an oral fall blood sugar medicine, can improve postprandial hyperglycemia and diabetes by takeda Japanese company successfully developed, belongs to the alpha glycosidase inhibitor (carbohydrates to delay intestinal drug absorption and achieves hypoglycemic effect), the mechanism of action is in intestine inhibits the disaccharides broken down into simple sugars disaccharides class hydrolase (alpha glycosidase enzymes), and thus delay the digestion and absorption of sugar, so as to improve the postprandial hyperglycemia. Health adults give sugar determination of load after exhaled hydrogen, the results confirmed that the dosage of this drug in clinical under has inhibitory effect on blood glucose increased. Normal rat oral medicine, this product after the inhibition of starch and sucrose, maltose load increased blood sugar, lactose and glucose, fructose and to Portugal after load increased blood sugar without inhibition. In vitro test mechanism, according to a study for the maltase from swine and rat small intestine and sucrase, this inhibitory effect is stronger; On the other hand, the pigs and rats alpha inhibition of pancreatic amylase.

Request a Quote
Category: Pharmaceutical Chemicals APISubcategory: Endocrine Drugs APIProduct ID: voglibose-83480-29-9
Payment & Shipping Terms Supply Capacity
Payment Terms: T/T, WU Production Capacity: 500kg/year
Min. Order: 1 Gram Packing: according to the customer's requirements
Means of Transport: Ocean, Air, Land Delivery Date: 7 days

Voglibose

CAS: 83480-29-9

Voglibose is an oral fall blood sugar medicine, can improve postprandial hyperglycemia and diabetes by takeda Japanese company successfully developed, belongs to the alpha glycosidase inhibitor (carbohydrates to delay intestinal drug absorption and achieves hypoglycemic effect), the mechanism of action is in intestine inhibits the disaccharides broken down into simple sugars disaccharides class hydrolase (alpha glycosidase enzymes), and thus delay the digestion and absorption of sugar, so as to improve the postprandial hyperglycemia. Health adults give sugar determination of load after exhaled hydrogen, the results confirmed that the dosage of this drug in clinical under has inhibitory effect on blood glucose increased. Normal rat oral medicine, this product after the inhibition of starch and sucrose, maltose load increased blood sugar, lactose and glucose, fructose and to Portugal after load increased blood sugar without inhibition. In vitro test mechanism, according to a study for the maltase from swine and rat small intestine and sucrase, this inhibitory effect is stronger; On the other hand, the pigs and rats alpha inhibition of pancreatic amylase.

Application: Used in the treatment of diabetes

CAS Number 83480-29-9
Molecular Formula C10H21NO7
Molecular Weight 267.28
Appearance white powder
Assay ≥99%
Place of Origin Sichuan,China (Mainland)
Brand MOSINTER
CAS 83480-29-9
Name Voglibose
Request a quote

Send an inquiry for Voglibose

By sending this inquiry, you acknowledge our Privacy Policy. We use these details only to answer your request.

We usually respond within one business day.

×
MOSINTER chemical operations

Request a Quote

By sending this inquiry, you acknowledge our Privacy Policy. We use these details only to answer your request.

We usually respond within one business day.

MOSINTER GROUP